New heart transplant strategy aims to swap toxic drugs for safer alternative
NCT ID NCT06478017
Summary
This study is testing if a drug called belatacept can safely replace part of the standard anti-rejection medication regimen for heart transplant patients. The goal is to protect the new heart from rejection while reducing the kidney damage often caused by long-term use of the standard drug, tacrolimus. Researchers will compare the new regimen against standard care in 66 recent heart transplant recipients over 18 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146)
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NYU Langone Health (Site # 71177)
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tampa General Hospital (Site # 71150)
RECRUITINGTampa, Florida, 33606, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Utah Medical Center (Site # 71126)
RECRUITINGSalt Lake City, Utah, 84132, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.